Wailoo A - Search Results

1

EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.

Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, Meads D, O'Dwyer J, Barton G, Irvine L. Hernandez Alava M, et al. Among authors: wailoo a. Value Health. 2018 Jan;21(1):49-56. doi: 10.1016/j.jval.2017.09.004. Epub 2017 Oct 18. Value Health. 2018. PMID: 29304940 Free article.

2

Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.

Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, Locker T, Ryan A. Goodacre S, et al. Among authors: wailoo a. Health Technol Assess. 2006 May;10(15):1-168, iii-iv. doi: 10.3310/hta10150. Health Technol Assess. 2006. PMID: 16707072 Free article. Review.

3

Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.

Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A, Nicholson KG. Wailoo AJ, et al. Value Health. 2008 Mar-Apr;11(2):160-71. doi: 10.1111/j.1524-4733.2007.00241.x. Value Health. 2008. PMID: 18380629 Free article.

4

Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.

Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Wailoo AJ, et al. Arthritis Rheum. 2008 Apr;58(4):939-46. doi: 10.1002/art.23374. Arthritis Rheum. 2008. PMID: 18383356 Free article.

5

Cost effectiveness of chest pain unit care in the NHS.

Oluboyede Y, Goodacre S, Wailoo A; ESCAPE Research Team. Oluboyede Y, et al. Among authors: wailoo a. BMC Health Serv Res. 2008 Aug 13;8:174. doi: 10.1186/1472-6963-8-174. BMC Health Serv Res. 2008. PMID: 18700961 Free PMC article.

6

Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.

Wailoo A, Tsuchiya A, McCabe C. Wailoo A, et al. Pharmacoeconomics. 2009;27(12):983-9. doi: 10.2165/11314100-000000000-00000. Pharmacoeconomics. 2009. PMID: 19908923 Free article.

7

Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.

Tosh JC, Wailoo AJ, Scott DL, Deighton CM. Tosh JC, et al. J Rheumatol. 2011 Aug;38(8):1593-600. doi: 10.3899/jrheum.101327. Epub 2011 May 15. J Rheumatol. 2011. PMID: 21572149

8

Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.

Hernández Alava M, Wailoo AJ, Ara R. Hernández Alava M, et al. Value Health. 2012 May;15(3):550-61. doi: 10.1016/j.jval.2011.12.014. Epub 2012 Mar 23. Value Health. 2012. PMID: 22583466 Free article.

9

Using health state utility values in models exploring the cost-effectiveness of health technologies.

Ara R, Wailoo A. Ara R, et al. Among authors: wailoo a. Value Health. 2012 Sep-Oct;15(6):971-4. doi: 10.1016/j.jval.2012.05.003. Epub 2012 Jun 15. Value Health. 2012. PMID: 22999149 Free article. Review.

10

The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.

Hernández Alava M, Wailoo A, Wolfe F, Michaud K. Hernández Alava M, et al. Among authors: wailoo a. Rheumatology (Oxford). 2013 May;52(5):944-50. doi: 10.1093/rheumatology/kes400. Epub 2013 Jan 21. Rheumatology (Oxford). 2013. PMID: 23339232 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters